Treatment Details – 10.6 months
|Patients: This Phase II study involved 29 patients with malignant pleural mesothelioma.|
Treatment: The treatment consisted of administration of the chemotherapy drug, vinorelbine (navelbine).
Toxicity: Grade 3-4 toxicities included neutropenia, leucopenia, constipation, and phlebitis
Results: The median overall survival from the time of first treatment was 10.6 months.
Support: The authors of the study acknowledged the support of Pierre-Fabre Oncology for subsidized drug costs.
Correspondence: Jeremy P.C. Steele, MD